...
首页> 外文期刊>Journal of Pain Research >An Examination of State and Federal Opioid Analgesic and Continuing Education Policies: 2016–2018
【24h】

An Examination of State and Federal Opioid Analgesic and Continuing Education Policies: 2016–2018

机译:审查州和联邦阿片类药物镇痛和持续教育政策:2016-2018

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Introduction: Opioid overdose deaths in the United States have climbed sharply over the past two decades. Simultaneously, increased awareness of inadequately treated chronic pain has resulted in increased opioid analgesic prescribing. The correlation between these two phenomena has led policymakers to posit that they are causally linked, and to implement policy changes supporting safe opioid prescribing. Purpose: To evaluate the impact of its Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) program, the US Food and Drug Administration (FDA) requested the opioid manufacturers responsible for implementing that program provide information regarding opioid policy changes from 2016 to 2018. FDA also requested a survey of state requirements for pain and opioid prescribing continuing education (CE), the number of prescribers affected by those requirements, the extent to which a REMS-compliant CE program would meet each state’s requirements, and the number of relevant CE programs available. Results: Results indicate that 527 federal and state opioid-related policies (statutes, rules/regulations, and guidelines) were approved during the 2016– 2018 study period. While the largest number of these policies focused on prescription drug monitoring programs, 170 specifically imposed limits on opioid prescribing and an additional 35 specifically referred to, or incorporated, the Centers for Disease Control and Prevention opioid prescribing guideline. We also found that 46 states and the District of Columbia mandated some amount of pain or opioid prescribing CE for prescribers renewing their licenses. These mandates potentially affected as many as 1.7 million prescribers. In 69% of cases, a REMS-compliant CE program would fully meet the state mandates for various types of prescribers. Conclusion: The severity and complexity of the problems of pain management and opioid overdose have led to large-scale intervention by policymakers. Assessing the impact of these changes is difficult, at best, but will be necessary if interventions are to be refined to increase their effectiveness.
机译:引言:在过去的二十年中,美国的阿片类药物过量死亡在过去的二十年中攀升。同时,增加对慢性疼痛的不充分良好的慢性疼痛的认识导致阿片类药物镇痛的规定增加。这两种现象之间的相关性使政策制定者提供了因果关系的问题,并实施支持安全阿片式规定的政策变革。目的:评估其阿片类药物镇痛风险评估和缓解战略(REMS)方案的影响,美国食品和药物管理局(FDA)要求责任实施该计划的阿片式制造商提供有关2016年至2018年的阿片政策变更的信息。FDA亦要求调查痛苦和阿片类药物规定继续教育(CE)的国家要求,受这些要求影响的规定规定的规定数量,符合REMS兼容的CE计划符合每个州的要求,以及相关CE计划的数量可用的。结果:结果表明,2016年2016年研究期间,批准了527名联邦和州与国家阿片类药物相关政策(法规,规则/条例和指南)。虽然最多的这些政策专注于处方药监测计划,但是170个专门对阿片类药物规定的限制以及另外35项,特别提及或纳入疾病控制和预防阿片类药物处方指南的中心。我们还发现,46个州和哥伦比亚地区强制了一些痛苦或阿片类药物,以便更新其许可证。这些授权可能影响到170万公章。在69%的案件中,符合REMS的CE计划将完全符合各种类型的公务员的国家任务。结论:疼痛管理和阿片类药物过量问题的严重程度和复杂性导致了政策制定者的大规模干预。评估这些变化的影响是困难的,并且如果要提高干预以提高其有效性,则必须必要。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号